The time-space coincidence expression of both ecto-5′-nucleotidase/CD73 and A2AR receptors offers new appealing therapeutic targets for immunotherapy and neuromuscular transmission reinforcement of myasthenia with minimal side effects. Here, NT5E is linked to Fatigable weakness.